Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug[1] related to nikethamide. It was mainly used in the treatment of barbiturate overdose[2] and chronic obstructive pulmonary disease,[3] but has now largely fallen into disuse.
Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.[4]
^Hirsh K, Wang SC (May 1975). "Respiratory stimulant effects of ethamivan and picrotoxin". The Journal of Pharmacology and Experimental Therapeutics. 193 (2): 657–63. PMID 1173598.
^Wheeldon PJ, Perry AW (July 1963). "The use of ethamivan in the treatment of barbiturate poisoning". Canadian Medical Association Journal. 89 (1): 20–2. PMC 1921664. PMID 14000228.
^Sproule BJ, Jans RL, Breitkreutz H, Mahon W (December 1964). "Effects of ethamivan in patients with chronic respiratory disease". Canadian Medical Association Journal. 91 (23): 1203–8. PMC 1928498. PMID 14226094.
^American Medical Association Dept of Drugs (1977). AMA Drug Evaluations (3rd ed.). Littleton, Mass.: Pub. Sciences Group. p. N-61. ISBN 978-0-88416-175-2. OCLC 1024170745.
Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug related to nikethamide. It was mainly...
Global Information
(what is this?) (verify)